Novavax
NVAX
77 hedge funds and large institutions have $27M invested in Novavax in 2019 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 22 increasing their positions, 23 reducing their positions, and 20 closing their positions.
103% more call options, than puts
Call options by funds: $11.5M | Put options by funds: $5.67M
4% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 23
4.65% less ownership
Funds ownership: 29.62% → 24.97% (-4.7%)
5% less funds holding
Funds holding: 81 → 77 (-4)
20% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 20
24% less capital invested
Capital invested by funds: $35.7M → $27M (-$8.67M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$732K |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$380K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$279K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$234K |
| 5 |
AC
Avenir Corporation
Alexandria,
Virginia
|
+$216K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.58M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$816K |
| 3 |
Two Sigma Advisers
New York
|
-$389K |
| 4 |
WG
Winton Group
London,
United Kingdom
|
-$384K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$294K |
NVAX Hedge Fund Activity: Q4 2019 in Review
77 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q4 2019, worth a combined $27M — down 24% from $35.7M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of NVAX and 16 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 22 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $732K. The largest seller was Morgan Stanley, cutting an estimated $1.58M.
- 77 institutional investors held Novavax (NVAX) as of Q4 2019, down from 81 in Q3 2019.
- Funds reported $27M of Novavax stock for Q4 2019, down 24% quarter-over-quarter.
- 16 funds opened new Novavax positions in Q4 2019 and 20 closed out, a net change of -4 holders.
- The largest Novavax buyer in Q4 2019 was D.E. Shaw & Co, an estimated $732K added.
- The largest Novavax seller in Q4 2019 was Morgan Stanley, an estimated $1.58M sold.
Based on aggregated 13F filings for Q4 2019.